Venous Thromboembolism
From the Journals
New ASH guidelines: VTE prevention and treatment in cancer patients
Opinion
ASH guidelines for venous thromboembolism: What family physicians need to know
A recommendation regarding the use of DOACs may ease some of the burden of monitoring patients on long-term Coumadin.
Conference Coverage
VTE prophylaxis is feasible, effective in some high-risk cancer patients
Conference Coverage
Factor XI inhibitor–based anticoagulation strategies gain ground
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”
Conference Coverage
VTEs tied to immune checkpoint inhibitor cancer treatment
Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint...
Conference Coverage
Switching to riociguat effective for some patients with PAH not at treatment goal
The clinical benefit of the switching to the sGC inhibitor was consistent across patient subgroups in the phase 4 REPLACE study.
Conference Coverage
Selexipag has no effect on daily activity in PAH patients
After 24 months of daily tracking, there was no benefit to increased daily activity for patients taking this drug.
Conference Coverage
HOME-PE trial clarifies which pulmonary embolism patients to treat at home
“Who’s happy with the HOME-PE trial? I think everybody.” – Dr. Stavros V. Konstantinides
Conference Coverage
TNF inhibitors cut odds of VTE in RA patients
Rather than increase risk for venous thromboembolism events, TNF inhibitors cut risk by nearly half, and other newer biologics lowered risk by...
Conference Coverage
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
Conference Coverage
Are providers asking about menstrual bleeding before/during anticoagulant therapy?